[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BIOTECHBATMAN Avatar @BIOTECHBATMAN BIOTECH BATMAN

BIOTECH BATMAN posts on X about $ions, $alny, $arwr, pricing the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #

Social category influence stocks

Social topic influence $ions #10, $alny #19, $arwr #7, pricing

Top assets mentioned Ionis Pharmaceuticals, Inc. Common Stock (IONS) Alnylam Pharmaceuticals, Inc. (ALNY) Arrowhead Research Corporation (ARWR)

Top Social Posts #

Top posts by engagements in the last XX hours

"Ioniss first siRNA clinical trial well underway and already has positive data. Target is apoC-III for biannual dosing. This seems strategic designed to kill any advantage a competitor may have taking the fast follower strategy. $ions $alny $arwr"
X Link @BIOTECHBATMAN 2025-10-07T13:03Z XXX followers, XXX engagements

"$ions truly firing on all cylinders. They should rapidly move towards $alny valuation as their pipeline increasingly moves to approved drugs with tech development (tissue spec ligands ultra long half-life modifications) that will make it challenging for any competitor to match"
X Link @BIOTECHBATMAN 2025-09-09T12:56Z XXX followers, XXX engagements

"Ionis will come after you in the market through pricing of their first-in-class drug and their follow-on drugs superior to your offerings. AND they will vigorously defend their IP/targets in court. The fast follower strategy will be economically unviable. $ions $alny $arwr"
X Link @BIOTECHBATMAN 2025-10-07T13:03Z XXX followers, XXX engagements